Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Z Usmani

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Leukemia|December 12, 2013
Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equalS Z Usmani, A Hoering
Mediterranean Journal of Hematology and Infectious Diseases|November 24, 2011
Therapy-related myeloid malignancies in myelomaX Papanikolaou, B Barlogie, S Z Usmani
Mcgill Journal of Medicine : MJM : an International Forum for the Advancement of Medical Sciences by Students|June 5, 2008
Barrett's esophagitis related bronchoesophageal fistula--the diagnostic value of persistent air leak in the ventilated settingO Halaweh, S Z Usmani, R Abouasaleh
Advances in Therapy|September 29, 2007
Angio-immunoblastic T-cell lymphoma in evolution: a case reportS Z Usmani, T Sahay, L Eisenberg
Leukemia|August 13, 2015
Defining and treating high-risk multiple myelomaS Z Usmani, P Rodriguez-Otero, M Bhutani, et al.
Blood Cancer Journal|January 17, 2015
Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomibS Atrash, A Tullos, S Panozzo, et al.
SAR and QSAR in Environmental Research|October 27, 2015
Insight into human protease activated receptor-1 as anticancer target by molecular modellingA N Hidayat, E Aki-Yalcin, M Beksac, et al.
Leukemia|June 19, 2012
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?S Z Usmani, J Crowley, A Hoering, et al.
Leukemia|August 1, 2014
Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myelomaC J Heuck, P Qu, F van Rhee, et al.
Blood Cancer Journal|August 8, 2015
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211S Z Usmani, R Sexton, S Ailawadhi, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Leukemia|December 12, 2013
Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equalS Z Usmani, A Hoering
Mediterranean Journal of Hematology and Infectious Diseases|November 24, 2011
Therapy-related myeloid malignancies in myelomaX Papanikolaou, B Barlogie, S Z Usmani
Mcgill Journal of Medicine : MJM : an International Forum for the Advancement of Medical Sciences by Students|June 5, 2008
Barrett's esophagitis related bronchoesophageal fistula--the diagnostic value of persistent air leak in the ventilated settingO Halaweh, S Z Usmani, R Abouasaleh
Advances in Therapy|September 29, 2007
Angio-immunoblastic T-cell lymphoma in evolution: a case reportS Z Usmani, T Sahay, L Eisenberg
Leukemia|August 13, 2015
Defining and treating high-risk multiple myelomaS Z Usmani, P Rodriguez-Otero, M Bhutani, et al.
Blood Cancer Journal|January 17, 2015
Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomibS Atrash, A Tullos, S Panozzo, et al.
SAR and QSAR in Environmental Research|October 27, 2015
Insight into human protease activated receptor-1 as anticancer target by molecular modellingA N Hidayat, E Aki-Yalcin, M Beksac, et al.
Leukemia|June 19, 2012
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?S Z Usmani, J Crowley, A Hoering, et al.
Leukemia|August 1, 2014
Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myelomaC J Heuck, P Qu, F van Rhee, et al.
Blood Cancer Journal|August 8, 2015
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211S Z Usmani, R Sexton, S Ailawadhi, et al.
Pageof 2